noted by Science<\/a> in 2023, the FDA usually required toxicity tests on one rodent species and one non-rodent species in order for drug approval to be granted. Some in the pharmaceutical industry have argued animal tests are slow and expensive.<\/p>\n\u201cFor too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,\u201d FDA Commissioner Martin Makary said in a statement.<\/p>\n
Makary said this move would offer newer treatments for patients more quickly while also reducing the cost of research and development.<\/p>\n
As part of this move, the FDA is releasing a roadmap for alternative methodologies that will encourage the use of computer modeling and artificial intelligence (AI); lab-grown human \u201corganoids\u201d and organ-on-a-chip systems; and it will also be updating its guidelines to allow for the consideration of these new methods.<\/p>\n
To determine the efficacy of these alternative evaluations, the FDA will be looking to “pre-existing, real-world safety data from other countries, with comparable regulatory standards, where the drug has already been studied in humans.”<\/p>\n
Kathy Guillermo, senior vice president of People for the Ethical Treatment of Animals (PETA), applauded the announcement on Thursday.<\/p>\n
“It\u2019s a significant step towards meeting the agency’s commitment to replace the use of animals \u2014 which PETA has worked hard to promote,” Guillermo said in a statement. “All animal use, including failed vaccine and other testing on monkeys at the federally-funded primate centers, must end, and we are calling on the FDA to further embrace 21st-century science.”<\/p>\n","protected":false},"excerpt":{"rendered":"
The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological products and drugs, instead moving toward alternative testing...<\/p>\n","protected":false},"author":1,"featured_media":994,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[14],"tags":[],"_links":{"self":[{"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/posts\/992"}],"collection":[{"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/comments?post=992"}],"version-history":[{"count":1,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/posts\/992\/revisions"}],"predecessor-version":[{"id":993,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/posts\/992\/revisions\/993"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/media\/994"}],"wp:attachment":[{"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/media?parent=992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/categories?post=992"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/thenewamore.com\/index.php\/wp-json\/wp\/v2\/tags?post=992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}